AZNAstraZenecaSigning up patients
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 80 (planned)
- Started
- Jun 4, 2026
- Main results expected
- May 1, 2029
- Fully finished
- Mar 23, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: ORR assessed at multiple timepoints during treatment period (each cycle is 28 days) and then every 12 months through the study completion, for 5 years. Timepoint for primary analysis is at completion of cycle 14.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07024706 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC